DexCom Inc (DXCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $30.44B
Last updated: Nov 17, 2026 at 4:39 PM ET
DexCom Inc (DXCM) Statistics
DexCom (DXCM) has a market cap of $30.44B and an enterprise value of $30.72B. Its trailing P/E of 30.7x is below its 5-year median of 67.5x. Its share count is down 4.19% from a year earlier.
Total Valuation
Enterprise value is 0.93% above the market cap, as debt exceeds cash.
| Market Cap | $30.44B |
|---|---|
| Enterprise Value | $30.72B |
| Latest price (Nov 17, 2026) | $82.04 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.0x and 12.1x. Its year-end P/E ranged from 31.8x to 374.4x from 2018 to 2025.
| P/E Ratio | 30.7x |
|---|---|
| Forward P/E | 29.7x |
| P/S Ratio | 6.0x |
| Forward P/S | 5.8x |
| P/B Ratio | 12.1x |
| P/TBV Ratio | 12.7x |
| P/FCF Ratio | 28.0x |
| P/OCF Ratio | 21.5x |
| PEG Ratio | 1.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 20.2x EBITDA and 28.2x free cash flow.
| EV / Earnings | 31.0x |
|---|---|
| EV / Sales | 6.0x |
| EV / EBITDA | 20.2x |
| EV / EBIT | 24.3x |
| EV / FCF | 28.2x |
Price Statistics
The stock is up 41.30% over 52 weeks and trades 2.47% below its 50-day average.
| Beta (1Y) | 0.74 |
|---|---|
| 52-Week Change | +41.30% |
| 1-Month Change | -4.58% |
| 3-Month Change | -8.72% |
| 6-Month Change | +22.54% |
| 5-Year Change | -47.18% |
| 10-Year Change | +320.71% |
| Total Return (1Y) | +41.30% |
| Total Return (3Y CAGR) | -7.89% |
| Total Return (5Y CAGR) | -12.74% |
| Return vs SPY (1Y) | +24.79% |
| Max Drawdown (1Y) | -22.61% |
| Max Drawdown (3Y) | -60.95% |
| Sharpe Ratio (1Y) | 0.83 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $84.12 |
| 200-Day Average | $75.17 |
| 52-Week Range | $56.72 to $92.59 |
| RSI (14 Days) | 48.8 |
| Average Volume (20 Days) | 5.20M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.74x current liabilities, and total debt is 0.49x shareholder equity.
| Current Ratio | 1.74x |
|---|---|
| Quick Ratio | 1.40x |
| Debt / Equity | 0.49x |
| Debt / EBITDA | 0.81x |
| Debt / FCF | 1.13x |
Returns and Efficiency
Return on invested capital is 26.22% over the last 12 months, against a 5-year average of 11.88%.
| Return on Equity (ROE) | 39.09% |
|---|---|
| Return on Assets (ROA) | 15.88% |
| Return on Invested Capital (ROIC) | 26.22% |
| Return on Capital Employed (ROCE) | 31.67% |
| ROE (5Y Average) | 22.13% |
| ROA (5Y Average) | 8.29% |
| ROIC (5Y Average) | 11.88% |
| Asset Turnover | 0.74x |
| Inventory Turnover | 2.49x |
| Receivables Turnover | 4.18x |
| Cash Conversion Cycle | -182 days |
Taxes
Income tax took 21.50% of pretax income over the last 12 months.
| Income Tax (TTM) | $271.40M |
|---|---|
| Effective Tax Rate | 21.50% |
Scores
DXCM has an Altman Z-Score of 7.49, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.49 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $5.10B over the last 12 months is up 13.03% from the 12 months before.
| Revenue | $5.10B |
|---|---|
| Revenue Growth (YoY) | +13.03% |
| Gross Profit | $3.24B |
| Operating Income | $1.22B |
| Pretax Income | $1.26B |
| Net Income | $991.00M |
| EBITDA | $1.54B |
| EBIT | $1.26B |
| Reported EPS (TTM) | $2.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 40.71% of the $6.24B in total assets.
| Cash and Equivalents | $961.40M |
|---|---|
| Total Debt | $1.24B |
| Net Debt | $282.30M |
| Net Debt Per Share | $0.75 |
| Working Capital | $1.66B |
| Shareholder Equity | $2.54B |
| Book Value Per Share | $6.77 |
| Tangible Book Value | $2.42B |
| Tangible Book Per Share | $6.46 |
| Total Assets | $6.24B |
| Total Liabilities | $3.70B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $316.10M of capital spending, operating cash flow left $1.10B of free cash flow.
| Operating Cash Flow | $1.41B |
|---|---|
| Capital Expenditures | $316.10M |
| Free Cash Flow | $1.10B |
| FCF Per Share | $2.91 |
| Depreciation and Amortization | $275.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 23.98%, against a 5-year average of 15.05%.
| Gross Margin | 63.42% |
|---|---|
| Operating Margin | 23.98% |
| Pretax Margin | 24.73% |
| Net Margin | 19.41% |
| EBITDA Margin | 30.12% |
| EBIT Margin | 24.73% |
| FCF Margin | 21.52% |
| Gross Margin (5Y Average) | 63.42% |
| Operating Margin (5Y Average) | 15.05% |
| Net Margin (5Y Average) | 13.55% |
Growth
Revenue grew 17.01% a year over 3 years, and EPS 33.93% a year.
| Revenue Growth (3Y CAGR) | +17.01% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.33% |
| EPS Growth (3Y CAGR) | +33.93% |
| EPS Growth (5Y CAGR) | +21.79% |
| FCF Growth (3Y CAGR) | +52.34% |
| FCF Growth (5Y CAGR) | +31.25% |
| Operating Income Growth (3Y CAGR) | +32.59% |
| Book Value Per Share Growth (2Y CAGR) | +17.65% |
| Tangible Book Per Share Growth (2Y CAGR) | +20.33% |
Dividends and Yields
DXCM does not pay a dividend. Its free cash flow yield is 3.57%.
| Earnings Yield | 3.26% |
|---|---|
| FCF Yield | 3.57% |
| Buyback Yield | 2.24% |
| Shareholder Yield | 2.24% |
Stock Splits
The last split was a 4-for-1 forward split on Jun 13, 2022.
| Last Split Date | Jun 13, 2022 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 4:1 |
Peer Position
Against 8 similar companies, DXCM has the 3rd highest P/E.
P/E RatioPeer median 19.3x
P/S RatioPeer median 3.0x
ROICPeer median 7.71%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.87%
| P/E Ratio | 30.7x vs 19.3x median |
|---|---|
| P/S Ratio | 6.0x vs 3.0x median |
| ROIC | 26.22% vs 7.71% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.03% vs +8.87% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.30% and EPS growth at 22.47% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.30% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +22.47% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DXCM
What is DXCM's market cap?
DexCom has a market cap of $30.44B. Its enterprise value, which adds debt and subtracts cash, is $30.72B.
What is DXCM's P/E ratio?
DexCom has a trailing P/E ratio of 30.7x and a forward P/E of 29.7x.
How many shares of DXCM are outstanding?
DexCom has 374.70M shares outstanding. The count is down 4.19% from a year earlier.
Does DXCM pay a dividend?
No. DexCom does not pay a dividend.
How much debt does DXCM have?
DexCom has $1.24B of total debt and $961.40M of cash and equivalents, a net debt position of $282.30M.
DXCM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors